Eculizumab
Contents
Description
Eculizumab is a humanized monoclonal antibody that inhibits terminal complement activation by binding to complement protein C5. It prevents the formation of the membrane attack complex and blocks complement-mediated cell destruction. While primarily indicated for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, it has shown efficacy in complement-mediated disorders including properdin deficiency complications.
Indications & Therapeutic Use
Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder, complement-mediated thrombotic microangiopathy
Linked Diseases:
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Eculizumab — GNH India
22 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | eculizumab |
| Brands | 1 brand available |
| Active Ingredient | eculizumab |
| Drug Class | Paroxysmal nocturnal hemoglobinuria |
| Manufacturer | Alexion Pharmaceuticals |
| Dosage Forms | IV infusion, 10mg/mL concentrate for solution |
| Medical Code | L04AA25 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00122226 |
| Countries | 9 countries |